Intensity Therapeutics Gross Profit

The latest gross profit for INTS is $-13K as of June 2026. That compares with $-7K in the prior-year period — down 85.7% year over year. That is below the sector sector average of $790M. Investors often review this figure alongside Intensity Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, INTS's gross profit moved from $-7K to $-13K — a 85.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Intensity Therapeutics's operating scale or balance-sheet position.

Against its sector companies, INTS currently prints $-13K for gross profit, while the sector average sits near $790M. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Intensity Therapeutics's growth, margins, and balance sheet.

A gross profit figure of $-13K for INTS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $790M. Explore the charts below for those layers of context.

After noting INTS's gross profit ($-13K), review year-over-year change from $-7K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.